Pharmaceutical Executive-02-01-2017

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pharmaceutical Executive

Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.

A new approach to reviving industry collaborations.

Pharmaceutical Executive
Columns

February 08, 2017

The key steps to easing rising complexity and cost factors.

Pharmaceutical Executive
From the Editor

February 08, 2017

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

Columns
Pharmaceutical Executive

February 06, 2017

Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.

Pharmaceutical Executive
Columns

February 01, 2017

Recent events you may have missed on the global pharma scene.

Pharmaceutical Executive

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Pharmaceutical Executive
Features

February 01, 2017

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

Pharmaceutical Executive
Special Sponsored Section

February 01, 2017

Despite serving as a regional hub for numerous leading global healthcare and life sciences companies-while simultaneously straddling the frontier of biomedical advancement and innovation-Singapore is reinventing itself yet again and spearheading a new model of Asian healthcare.

Issue PDF
Pharmaceutical Executive

February 01, 2017

Click the title above to open the Pharmaceutical Executive February 2017 issue in an interactive PDF format.

Columns
Pharmaceutical Executive

January 01, 2017

The pursuit of a harmonized European approach to assessing the value of new medicines continues to face roadblocks.